Composition to be electrospun
By using biocompatible polymers and surfactants in water, the problems of low productivity of electrospun fibers and fiber defects in water are solved, and efficient and sustainable industrial-scale electrospun fiber production is achieved, reducing the production of electrospun fibers in the water. environmental impact.
Patent Information
- Application Number
- CN202380030224.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-08
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art has problems of low productivity and fiber defects in the production of electrospun polymer fibers in water, and traditional solvents are harmful to the environment, making it difficult to achieve sustainable electrospun fiber production on an industrial scale.
The surface tension of the composition to be electrospinned comprising a biocompatible polymer is reduced by electrospinning the first compound, the spinning promoter and the surfactant, by electrospinning the first compound, the spinning promoter and the surfactant, Stabilize the electrospinning process, improve yield and avoid fiber defects.
The efficient production of constant diameter, regular continuous nanofibers in water is achieved, which improves the productivity of electrospun fibers on industrial scale, avoids fiber defects, and reduces environmental impact through biologically sourced surfactants.
Smart Images

Figure BDA0005058866410000161
Abstract
Description
Technical Field
[0001] The present invention relates to a composition to be electrospun, ie allowing the production of nanofibers by electrospinning. More specifically, the composition to be electrospun is of a type based on a polymer, preferably a biocompatible polymer. Background Art
[0002] Electrospinning processes are known that allow nanofibers, i.e. continuous fibers with a diameter in the nanometer range, to be obtained from a composition based on the polymer compound to be electrospun, subjected to an electric field. Depending on the type of compound to be electrospun, the nanofibers obtained can be applied in any industry, such as the medical, military defense, environmental, biotechnological, energy or cosmetic industries.
[0003] For environmental reasons, electrospinning is often performed using environmentally friendly solvents, especially in water. However, electrospinning of polymers in pure water is not straightforward due to the surface tension and the viscosity of the obtained compounds.
[0004] To overcome this problem, attempts have been made to reduce the surface tension and viscosity of water, for example by electrospinning in aqueous ammonium salt solutions, then in high pH solutions, or even in water at 40°C in the presence of dimethylformamide DMF. Tests have also been carried out with hexafluoroisopropanol HFIP or ethanol. However, testing with hexafluoroisopropanol HFIP or ethanol is not ecologically favorable.
[0005] Compositions to be electrospun based on biocompatible polymers have been proposed which also comprise electrospinning facilitators, which make electrospinning in water possible. But even with the compositions described so far, industrial-scale fiber production can still be improved further, especially in terms of productivity.
[0006] Therefore, there is a need to develop a composition to be electrospun that overcomes at least one of the disadvantages of the prior art.
[0007] For this purpose, it is necessary to solve the technical problems of the composition to be electrospun, thus allowing the production of electrospun fibers without environmental impact by electrospinning and on an industrial scale.
[0008] In particular, it is an object of the present invention to provide a composition to be electrospun which can be electrospun in water and on an industrial scale with acceptable yields.
[0009] Another object of the present invention is to provide a composition to be electrospun which allows the production of continuous nanofibers or in any case fibers having a constant or nearly constant diameter and without defects.
[0010] Another object was to develop a method for preparing the above-mentioned composition to be electrospun.
[0011] The Applicant has devised, tested and embodied the present invention to overcome the shortcomings of the state of the art and to obtain these and other purposes and advantages. Summary of the invention
[0012] The invention is set forth and characterized in the independent claims. The dependent claims describe other characteristics of the invention or variants to the main inventive idea.
[0013] According to the above-mentioned purpose, and in order to solve the above-disclosed technical problems in a novel and original way, and also to achieve considerable advantages compared with the prior art, the composition to be electrospun according to the present invention comprises a first compound to be electrospun, a spinning accelerator and a surfactant. The role of the spinning accelerator is to promote the spinning of the first compound, in particular to stabilize the electrospinning process to obtain regular fibers. The surfactant has the function of improving the electrospinning process, thereby allowing a higher delivery rate and therefore a higher yield, while avoiding the formation of defects in the fiber. This improvement is achieved by reducing the surface tension of the composition, while the conductivity of the composition is also reduced. Specifically, it has been observed that the use of a surfactant can avoid dripping during electrospinning.
[0014] The first compound to be electrospun is a biocompatible polymer suitable for electrospinning and is selected from a first polysaccharide, collagen, gelatin, albumin, elastin and their derivatives. Advantageously, the first polysaccharide is selected from xanthangum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, cellulose derivatives, starch, gelatin, β-glucan, glycosaminoglycan, mucopolysaccharide, water-soluble polysaccharide and their derivatives.
[0015] Preferably, the cellulose derivative is selected from hydroxypropyl methylcellulose HPMC, hydroxypropyl cellulose HPC, hydroxyethyl cellulose HEC, sodium carboxymethyl cellulose Na-CMC. Glycosaminoglycan GAG or mucopolysaccharide can be selected from chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate and hyaluronic acid HA. Water-soluble polysaccharides can be selected from galactomannan, xylan, gum arabic, gum ghatti, glucomannan, acemannan, soluble dietary fiber, glycogen, straight-chain starch, and polysaccharides derived from plants, bacteria and fungi.
[0016] The spinning facilitator is a polymeric carrier, possibly uncharged, selected from a second polysaccharide having a chemical composition different from the first polysaccharide, and possibly the presence of poly(ethylene oxide) PEO. Advantageously, the polymeric carrier (even possibly uncharged) is also biocompatible.
[0017] Preferably, the electrospinning accelerator is selected from pullulan and alginate, possibly mixed with poly(ethylene oxide). The accelerator may also include a mixture of pullulan and alginate. More preferably, the chemical composition of the accelerator is different from that of the first compound to be electrospun, that is, the first compound to be electrospun is not pullulan or alginate.
[0018] The surfactant is advantageously a biosurfactant, i.e. a surfactant of biological and organic origin. Specifically, the surfactant is obtained by fermentation of gram-positive microorganisms. This surfactant has a biological origin, making it biocompatible.
[0019] Preferably, the surfactant is selected from lipopeptides, in particular lipopeptides obtained from Bacillus sp. More preferably, the surfactant is selected from the surfactin family, in particular from surfactin, pumilacidin and lichenysin.
[0020] Advantageously, the concentration of the surfactant ranges from 0.1% to 5%, more advantageously from 0.2% to 2%, even more advantageously from 0.5% to 1% by weight relative to the total weight of the composition.
[0021] According to an embodiment, the pH of the composition is maintained at a slightly alkaline value, in particular between 6 and 7. To this end, an alkaline compound, such as NaOH, is suitably added to the composition.
[0022] According to an embodiment, the composition further comprises an active ingredient. Such an active ingredient may, for example, be selected from cosmetic active ingredients, pharmaceutical active ingredients and nutraceutical active ingredients.
[0023] According to an embodiment, the composition further comprises a stabilizer suitable for improving the stability of the fibers obtained after electrospinning. Preferably, the stabilizer is a crosslinkable polymer.
[0024] The advantage of the above composition is that it is possible to prepare cosmetic, pharmaceutical or nutritional products based on natural polymers in which the local concentration of the compound of interest is much higher than that obtainable with conventional preparations. This is due to the fact that the compound of interest is precisely integrated into the structure of the final product. With known compositions, it is almost impossible to achieve high concentrations, even with polysaccharides, collagen, gelatin, albumin, elastin and their low molecular weight derivatives, because the viscosity of the product increases too much and therefore it is impossible to exceed 5 to 10% by weight. With the composition of the invention, it is possible to obtain products that allow the application of concentrations of up to 50% by weight of the compound of interest.
[0025] It should be noted that for the composition according to the invention, different types of uses may be envisaged, depending on the electrospun compound, but also on the active ingredient; in particular, uses in the cosmetic, pharmaceutical or nutraceutical industries may be provided. More precisely, the cosmetic use may provide a topical skin application as mentioned above, while the pharmaceutical and nutraceutical use may enable the release of the active ingredient, drug and / or supplement in vivo.
[0026] According to one aspect, a method for preparing a composition to be electrospun is also provided, wherein a first compound to be electrospun, a spinning accelerator and a surfactant are mixed.
[0027] The first compound to be electrospun is a biocompatible polymer suitable for electrospinning and is selected from the first polysaccharide, collagen, albumin, gelatin, elastin and their derivatives. Advantageously, the first polysaccharide is selected from xanthan gum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, cellulose derivatives, starch, β-glucan, glycosaminoglucan, mucopolysaccharide, water-soluble polysaccharide and their derivatives. Preferably, the cellulose derivative is selected from hydroxypropyl methylcellulose HPMC, hydroxypropyl cellulose HPC, hydroxyethyl cellulose HEC, sodium carboxymethyl cellulose Na-CMC. Glucosaminoglucan GAG or mucopolysaccharide can be selected from chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate and hyaluronic acid HA. Water-soluble polysaccharides can be selected from galactomannan, xylan, gum arabic, caramel gum, glucomannan, acemannan, soluble dietary fiber, glycogen, straight-chain starch, and polysaccharides derived from plants, bacteria and fungi.
[0028] The spinning accelerator is an uncharged polymer carrier selected from a second polysaccharide having a chemical composition different from the first polysaccharide, and poly(ethylene oxide) PEO may be present. Advantageously, the uncharged polymer carrier is also biocompatible. Preferably, the second polysaccharide of the composition is selected from alginate and pullulan.
[0029] Surfactants are biosurfactants, i.e. surfactants of biological and organic origin. Specifically, biosurfactants are obtained by fermentation of Gram-positive microorganisms. Such surfactants have a biological origin, making them biocompatible.
[0030] Preferably, the surfactant is selected from lipopeptides, in particular lipopeptides obtained from Bacillus. More preferably, the surfactant is selected from the surfactin family, in particular from surfactin, brevicaulin and lichenin.
[0031] According to an embodiment, the method involves adding a surfactant before starting electrospinning of the composition, thereby stabilizing production. For example, the method may involve dissolving the first compound, the electrospinning accelerator, and the surfactant in water, preferably in respective separate aliquots of water, and mixing them.
[0032] According to an embodiment, the method envisages maintaining the pH of the composition at a slightly alkaline value, ie between 6 and 7, by adding an alkaline compound. The alkaline compound may be any base, such as NaOH.
[0033] According to an embodiment, the method comprises adding an active ingredient. Such an active ingredient may, for example, be selected from cosmetic active ingredients, pharmaceutical active ingredients and nutraceutical active ingredients.
[0034] According to an embodiment, the method further requires the addition of a stabilizer suitable for improving the stability of the fibers obtained after electrospinning. Preferably, the stabilizer is a cross-linkable polymer.
[0035] According to another aspect, a patch product preferably applied to the skin is provided, the patch product being composed of a membrane substrate that can be absorbed by the skin. The membrane substrate is an electrospun membrane substrate. The electrospun membrane substrate is composed of at least one fiber (preferably nanofiber), particularly in the form of a nonwoven fabric.
[0036] The at least one fiber forming the membrane substrate in turn consists of a first electrospinning compound, an electrospinning accelerator and a surfactant. These compounds are of the type defined above for the composition and method.
[0037] According to an embodiment, the fibers have a planar shape, ie a flat cross-section. DETAILED DESCRIPTION
[0038] Unless otherwise defined, all technical and scientific terms used herein and hereinafter have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present disclosure, methods and materials are described below by way of example. In the event of a conflict, this specification (including definitions) shall prevail. Materials, methods and examples are intended to be illustrative only and should not be construed as limiting.
[0039] Unless otherwise stated, all measurements are made at 25° C. (room temperature) and atmospheric pressure. Unless otherwise stated, all temperatures are expressed in degrees Celsius.
[0040] Unless otherwise indicated, all percentages and ratios shown are intended to be by weight of the total composition (w / w).
[0041] Unless otherwise indicated, all percentage ranges indicated herein are intended to sum to 100% relative to the total composition.
[0042] Unless otherwise stated, all ranges set forth herein are intended to be inclusive of the endpoints, including those endpoints reporting a range "between" two values.
[0043] Unless otherwise stated, ranges resulting from the overlap or combination of two or more disclosed ranges are also included in the present disclosure.
[0044] Unless stated otherwise, ranges that may result from combinations of two or more of the disclosed point values are also included in the disclosure.
[0045] Unless otherwise stated, where water is mentioned, it is distilled water.
[0046] The composition comprises a first compound to be electrospun, which is a biocompatible polymer suitable for electrospinning and is selected from xanthan gum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, hydroxypropyl methylcellulose HPMC, hydroxypropyl cellulose HPC, hydroxyethyl cellulose HEC, sodium carboxymethyl cellulose Na-CMC, albumin, starch, gelatin, collagen, elastin, β-glucan, chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate, hyaluronic acid HA, galactomannan, xylan, gum arabic, carrageenan, glucomannan, acemannan, soluble dietary fiber, glycogen, straight-chain starch, polysaccharides derived from plants, bacteria and fungi, and derivatives thereof.
[0047] Such compounds or classes of compounds have the property of possibly changing the viscosity of liquids, which makes them suitable for forming regular electrospun fibers with good mechanical and absorptive properties. They are also all biocompatible, of natural origin, and can be used in the food, pharmaceutical and / or cosmetic industries.
[0048] Specifically, xanthan gum, dextran, carrageenan, Na-CMC, starch, gelatin and carrageenan are used as thickeners, stabilizers and may also be used as gelling agents in the food industry. In addition, xanthan gum is used as a stabilizer for suspensions and emulsions in the pharmaceutical and cosmetic industries, guar gum is also used as a thickener and gelling agent in the pharmaceutical and cosmetic industries, and carrageenan is used as an inactive excipient in the pharmaceutical industry. Dextran is also used as a thickener in the pharmaceutical industry.
[0049] Chitosan is used as an excipient in the food industry, low-calorie diets and pharmaceutical industry, especially for inhalation products. On the other hand, pectin is used as a gelling agent in the food industry and as a dietary agent and probiotic in the pharmaceutical industry.
[0050] Agar agar, galactomannan and glucomannan are used as gelling agents in the nutraceutical industry.
[0051] Among cellulose derivatives, HPMC is used as a stabilizer and viscosity regulator in the food industry, and as an excipient or eye drops for oral medicines in the pharmaceutical field. HPC is used as a food additive, and in the pharmaceutical industry as eye drops or as a binder for tablets. HEC is used as a thickener and gelling agent in the pharmaceutical and cosmetic industries.
[0052] Beta-glucan is used as dietary fiber, as is xylan. Chondroitin sulfate is used as a dietary supplement and is also used to treat osteoarthritis symptoms. Dermatan sulfate, heparin, and heparan sulfate are known as anticoagulants in the pharmaceutical industry.
[0053] Gum Arabic is used as a stabilizing excipient and viscosity regulator in the food industry. Acemannan is known in the pharmaceutical industry to have immunostimulatory properties.
[0054] It should be noted that some of these compounds, such as starch, elastin, hyaluronic acid, heparin, collagen, pectin, β-glucan, chondroitin sulfate, dermatan sulfate, heparan sulfate and their derivatives, have their own functions in the cosmetic, pharmaceutical or food industries. Therefore, electrospinning these compounds is advantageous because the use of corresponding fibers will allow these compounds to be applied in higher doses than known solutions, thereby achieving greater effects.
[0055] In the case where the first compound to be electrospun is hyaluronic acid, it may be linear or cross-linked and may have a high mass, for example a mass of about one million Daltons or even higher, or alternatively a low mass, typically a mass of about 10,000 Daltons or lower. It is also possible to provide a mixture of linear hyaluronic acid and cross-linked hyaluronic acid, thereby adjusting the rigidity of the yarn to be obtained and the three-dimensional structure of the film that can be obtained by depositing the yarn on a support.
[0056] Advantageously, the first compound is diluted in an aqueous or water-based solution in a concentration of, for example, 0.1 to 30% by weight, preferably 1 to 20% by weight, more preferably 5 to 15% by weight.
[0057] The composition to be electrospun also comprises a spinning facilitator, which is advantageously a biocompatible, uncharged polymer carrier. It is selected from alginate (possibly in the presence of PEO) or pullulan. The spinning facilitator is preferably pullulan, as it allows to obtain the best results.
[0058] In the case of alginate mixed with PEO, they can be diluted in an aqueous or water-based solution, respectively, at a concentration of 0.1% to 30% by weight, preferably 1% to 20% by weight, more preferably 5% to 15% by weight. If PEO is present, the weight ratio of the alginate:PEO mixture is preferably in the range of 5:1 to 1:5, more preferably 2:1 to 1:2. The best electrospinning results are obtained with a weight ratio equal to 1:1.
[0059] Pullulan may be diluted in a water-based or aqueous solution, preferably at a concentration of 0.1 to 30% by weight, preferably 1 to 20% by weight, more preferably 5 to 15% by weight.
[0060] The first compound to be electrospun and the accelerator are preferably mixed in a weight ratio of (first compound): accelerator of 10:1 to 1:10, more preferably 5:1 to 1:5, even more preferably 2:1 to 1:2. It has been found that the best results are obtained using a composition in which the weight ratio of the first compound to the accelerator is 1:1.
[0061] The composition also comprises a surfactant selected from biosurfactants, ie surfactants of biological and organic origin, as opposed to surfactants of bacterial origin.
[0062] In particular, the surfactant of the composition is advantageously obtained by fermentation of Gram-positive microorganisms.
[0063] More precisely, the biosurfactant is selected from lipopeptides, in particular lipopeptides derived from fermentation of Bacillus organisms, more particularly lipopeptides with a low molecular weight, such as lipopeptides with a molecular weight of at most 10000 g / mol, preferably at most 5000 g / mol, more preferably at most 2500 g / mol.
[0064] There are several families among these lipopeptides, such as surfactin, iturin, fengycin, kurstatin and locillomycin. These families of lipopeptides differ from each other in the type and sequence of amino acid residues, the nature of the peptide cycle, and the nature, length and branching of the fatty acid chains. However, all of these families have the properties of surfactants.
[0065] Preferably, the biosurfactant of the composition is selected from the surfactin family.
[0066] In the surfactin family there are surfactins themselves, which can be produced by different branches of the genus Bacillus, especially by B. subtilis, but also by other Bacillus such as B. natto or B. circulans. Their structure includes a lactone ring formed by seven amino acids with a characteristic chiral sequence (L-Glu, L-Leu, D-Leu, L-Val, L-Asp, D-Leu and L-Leu, wherein the first and the last amino acids are linked by ester bonds to form a lactone ring). Surfactins have a β-hydroxy fatty acid chain with a length of thirteen to sixteen carbon atoms. Although more than 30 homologues are known in surfactin, they all have the same chiral LLDLLDL amino acid sequence in the lactone ring. Homologues are molecules of the same kind, but are not isomers.
[0067] The surfactin family also includes pumilins obtainable from the B. pumilus clade with variants A to F. Compared to surfactin, the amino acid at position 7 in pumilins is substituted with L-Val or L-Ile.
[0068] The surfactin family finally includes lichenin, which is obtained primarily from B. licheniformis and differs from surfactin in that position 1 of the lactone ring of L-glutamic acid is replaced by L-glutamine.
[0069] Surfactin, brevidin and lichenin contain five hydrophobic residues (Leu, Val or Ile) and long secondary aliphatic chains, which give them strong surfactant properties. In fact, it has been demonstrated that compounds of the surfactin family of high purity can reduce the surface tension of water from 72 mN / m to 27 mN / m at a concentration of 0.0005% by weight. Surfactin is stable and soluble in water over a wide pH (5 to 13) and temperature range, which makes them particularly suitable for electrospinning in aqueous solutions.
[0070] Preferably, the biosurfactant is surfactant. Specifically, the solubility of surfactant or biosurfactant in water at 20°C may be 548 g / L, the critical micelle concentration (CMC) may be 0.0003% by weight, and the ratio of hydrophilic group to hydrophobic group (HLB) may be 10 to 17, more preferably 15.9 to 16.5 (considering the length of C 13 -C 15 of β-hydroxy fatty acid chains) or 10 to 12, a critical packing parameter (CPP) of less than 0.33, more preferably 0.12 to 0.16, and / or a pKa value of 4.271 to 3.727.
[0071] It should be noted that the above HLB values are calculated using the Griffin method.
[0072] Typically, the biosurfactant is present in a concentration of less than 5%, preferably less than 2%, more preferably from 0.5% to 1% by weight based on the weight of the composition.
[0073] The composition also comprises at least one active ingredient of the pharmaceutical, nutraceutical and / or cosmetic type.
[0074] It should be noted that active ingredients can have various types of functions regardless of their field of action.
[0075] The cosmetic active ingredients may be of the following types: anti-seborrheic drugs (e.g., sebacic acid, azelaic acid), anti-sebum drugs (e.g., charcoal powder), antimicrobial agents (e.g., climbazole, piroctone olamine salt), antioxidants (e.g., ascorbic acid, tocopherol, coenzyme Q10, resveratrol, glutathione), antiperspirants (e.g., aluminum chlorohydrate, aluminum sesquichlorohydrate), astringents (e.g., lemon flower extract, calcium lactate), bleaching agents (e.g., glabridin, ammonium persulfate), cleansers (e.g., sodium cocoyl glutamate), deodorants (e.g., triethyl citrate, zinc ricinoleate), exfoliants (e.g., glycolic acid, malic acid), acid, mandelic acid), flavoring agents (e.g. citral, honey), fragrances (e.g. d,l-limonene, coumarin), humectants (e.g. glycerol, propylene glycol), keratolytic agents (e.g. chloroacetic acid, salicylic acid), moisturizers (e.g. aloe vera leaf extract), fragrances (e.g. geraniol, linalool), emollients (e.g. triolein, squalene), fresheners (e.g. menthol, menthyl lactate), moisturizing emollients (e.g. panthenol, allantoin), skin care agents (e.g. sphingolipids, zinc oxide), smoothing agents (e.g. castor seed oil), soothing agents (e.g. witch hazel extract, chamomile (Camomilla rictica) extract, bisabolol) or tonics (e.g. arnica, capsicum extract), UV filters (e.g. methylene bisbenzotriazolyl tetramethylbutylphenol, ethylhexyl methoxycinnamate, caffeine, caffeine, theobromine, theophylline).
[0076] The active pharmaceutical ingredient may be of the following types: 5-α-reductase inhibitors (e.g. finasteride), 5-aminosalicylate (e.g. aminosalicylic acid), 5HT3 receptor antagonists (e.g. ondansetron), ACE inhibitors and calcium antagonists (e.g. amlodipine / benazepril), ACE inhibitors and thiazides (e.g. hydrochlorothiazide), adamantane antivirals (e.g. amantadine), adrenocorticosteroid inhibitors (e.g. aminoglutethimide), adrenergic bronchodilators (e.g. salbutamol), hypertensive crisis treatment agents (e.g. diazoxide), pulmonary hypertension treatment agents (e.g. treprostinil), aldosterone receptor antagonists (e.g. spironolactone), alkylating agents (e.g. cyclophosphamide), allergens (e.g. house dust mite allergen extracts), α- glucosidase inhibitors (e.g. miglitol), anti-amoebics (e.g. metronidazole), aminoglycosides (e.g. tobramycin), aminopenicillins (e.g. amoxicillin), aminosalicylates (e.g. aminosalicylic acid), AMPA receptor antagonists (e.g. perampanel), amylin analogs (e.g. pramlintida), analgesics (e.g. acetaminophen), androgens and anabolic steroids (e.g. testosterone), angiotensin-converting enzyme inhibitors (e.g. ramipril), angiotensin II inhibitors with calcium channel blockers (e.g. amlodipine / olmesartan), angiotensin II inhibitors with thiazides (e.g. hydrochlorothiazide / olmesartan), angiotensin receptor blockers anti-angiogenic ophthalmic agents (e.g., aflibercept), anti-CTLA-4 monoclonal antibodies (e.g., ipilimumab), monoclonal anti-PD-1 antibodies (e.g., nivolumab), anti-adrenergic agents (centrally acting) with thiazides (e.g., hydrochlorothiazide / methyldopa), anti-adrenergic agents (peripherally acting) with thiazides (e.g., polythiazide / prazosin), centrally acting anti-adrenergic agents (e.g., guanfacine), peripherally acting anti-adrenergic agents anticonvulsants (e.g., lacosamide), antidepressants (e.g., bupropion), antidiarrheals (e.g., loperamide), antidiuretics (e.g., desmopressin), antidotes (e.g., naltrexone), analgesics (e.g., dronabinol), anticoagulants (e.g., phytonadione), anticonvulsants (e.g., lacosamide), antidepressants (e.g., bupropion), antidiarrheals (e.g., loperamide), antidiuretics (e.g., desmopressin), antidotes (e.g., naltrexone),Antifungal agents (e.g. griseofulvin), antigonadotropins (e.g. danazol), antigout agents (e.g. colchicine), antihistamines (e.g. cetirizine), hypolipidemic agents and combinations (e.g. ezetimibe / simvastatin), anti-hypercaemic agents (e.g. febuxostat), antimalarial agents (e.g. doxycycline), antimalarial combinations, antimalarial quinolines (e.g. hydroxychloroquine), antimanic agents (e.g. lithium), antimetabolites (e.g. capecitabine), antiemycranic agents (e.g. rizatriptan), antineoplastic agents (e.g. isotretinoin), antineoplastic drug combinations (e.g. letrozole / ribociclib), antineoplastic antidotes (e.g. amifostine), Antineoplastic interferons (e.g., interferon alfa-2b), anti-Pseudomonas aeruginosa penicillins (e.g., carbenicillin), antipsoriatics (e.g., acitretin), antipsychotics (e.g., haloperidol), antirheumatic drugs (e.g., adalimumab), antiseptics and antiseptics, antithyroid agents (potassium iodide), antitoxins and antivirals (e.g., polyvalent antivenom (crotalinidae) toxins), cough suppressants (e.g., dextromethorphan), antiviral adjuvants (e.g., ritonavir), antiviral interferons (e.g., peginterferon alfa-2a), aromatase inhibitors (e.g., anastrozole), atypical antipsychotics (e.g., aripiprazole), azole antifungals (e.g., fluconazole), bacterial vaccines (e.g., 13-valent pneumococcal vaccines), anticonvulsants barbiturates (e.g., primidone), barbiturates (e.g., phenobarbital), BCR-ABL tyrosine kinase inhibitors (e.g., imatinib mesylate), anticonvulsants benzodiazepines (e.g., diazepam), benzodiazepines (e.g., clonazepam), beta-blockers with thiazides (e.g., bisoprolol / hydrochlorothiazide), beta-lactamase inhibitors (e.g., clavulanic acid), bile acid sequestrants (e.g., colesevelam), bisphosphonates (e.g., zoledronic acid), BTK inhibitors (e.g., ibrutinib), calcimimetics (e.g., cinacalcet), calcineurin inhibitors (e.g., tacrolimus), calcitonin, calcium channel blockers (e.g., verapamil), carbamates Anticonvulsants (e.g., felbamate), carbapenems (e.g., doripenem), carbapenem / β-lactamase inhibitors (e.g., meropenem / vilbobactam), anticonvulsants carbonic anhydrase inhibitors (e.g., topiramate), carbonic anhydrase inhibitors (e.g., acetazolamide), regenosadase stress agents, beta-cardioselective beta-blockers (e.g., nebivolol), catecholamines (e.g., epinephrine), CD20 monoclonal antibodies (e.g., ocrelizumab), CD30 monoclonal antibodies (e.g., brentuximab), CD33 monoclonal antibodies (e.g., gemtuzumab), CD38 monoclonal antibodies (e.g., CD52 monoclonal antibodies) (e.g., alemtuzumab), CDK 4 / 6 inhibitors (e.g., palbociclib), cephalosporins / β-lactamase inhibitors (e.g., avibactam / ceftazidime), cerumenolytics (e.g., carbamide peroxide),CFTR combinations (e.g., ivacaftor / lumacaftor), CFTR potentiators (e.g., ivacaftor), CGRP inhibitors (e.g., erenumab), chelators (e.g., deferasirox), chemokine receptor antagonists (e.g., maraviroc), chloride channel activators (e.g., lubiprostone), cholesterol absorption inhibitors (e.g., ezetimibe), cholinergic agonists (e.g., cevimeline), cholinergic muscle stimulants (e.g., pyridostigmine), cholinesterase inhibitors (e.g., donepezil), central nervous system stimulants (e.g., phentermine), colony stimulating factors (e.g., filgrastim), birth control pills (e.g., levonorgestrel), adrenocorticotropic hormone, coumarins, and indanediones (e.g., warfarin), c ox-2 inhibitors (e.g. celecoxib), decongestants (e.g. pseudoephedrine), diarylquinolines (e.g.), anticonvulsants dibenzazepines (e.g. carbamazepine), digestive enzymes (e.g. lactase), dipeptidyl peptidase 4 inhibitors (e.g. sitagliptin), dopaminergic anti-parkinsonian drugs (e.g. ropinirole), drugs for the treatment of alcohol dependence (e.g. acamprosate), echinocandins (e.g. caspofungin), inhibitors (e.g. erlotinib), estrogen receptor antagonists (e.g. fulvestrant), estrogens (e.g. estradiol), expectorants (e.g. guaifenesin), factor Xa inhibitors (e.g. rivaroxaban), anticonvulsants fatty acid derivatives (e.g. divalproex sodium), fibric acid derivatives (e.g. fenofibrate), first generation cephalosporins (e.g. cephalosporins sporexin), fourth-generation cephalosporins (e.g., cefepime), gallstone dissolving agents (e.g., ursodeoxycholic acid), GABA analogs (e.g., gabapentin), GABA reuptake inhibitors (e.g., tiagabine), general anesthetics (e.g., propofol), GI stimulants (e.g., metoclopramide), glucocorticoids (e.g., budesonide), glucose-raising agents (e.g., glucagon), antibiotics (e.g., vancomycin), platelet glycoprotein inhibitors (e.g., tirofiban), glycylcyclines (e.g., tigecycline), gonadotropin-releasing hormones (e.g., leuprolide), gonadotropin-releasing hormone antagonists (e.g., elagolix), gonadotropins (e.g., chorionic gonadotropin), group I antiarrhythmics (e.g., phenytoin), I Group I antiarrhythmics (e.g., propranolol), Group III antiarrhythmics (e.g., dronedarone), Group IV antiarrhythmics (e.g., verapamil), Group V antiarrhythmics (e.g., digoxin), growth hormone receptor blockers (e.g., pegvisomant), growth hormones (e.g., somatostatin), guanylate cyclase C agonists (e.g., linaclotide), Helicobacter pylori eradicants (e.g., bismuth potassium citrate / metronidazole / tetracycline), H2 antagonists (e.g., ranitidine), hedgehog pathway inhibitors (e.g., vismodegib), heparin antagonists (e.g., protamine), HER2 inhibitors (e.g., neratinib), herbal products (e.g., 5-hydroxytryptophan, aloe vera), histone deacetylase inhibitors (e.g., romidepsin),Hormonal / antineoplastic agents (e.g., medroxyprogesterone), hydantoin anticonvulsants (e.g., phenytoin), hydrazide derivatives (e.g., isoniazid), immunoglobulins, impotence agents (e.g., sildenafil), incretin mimetics (e.g., liraglutide), inotropes (e.g., digoxin), insulin and its derivatives (e.g., insulin glargine), insulin-like growth factors (e.g., mecasermin), interferons (e.g., interferon beta-1a), interleukin inhibitors (e.g., dupilumab), interleukins (e.g., aldesleukin), iron (e.g., ferrous sulfate), ketolides (e.g., telithromycin), laxatives (e.g., bisacodyl), antileprosy agents (e.g., clofazimine), leukotriene modifiers (e.g., montelukast), lincomycin derivatives (e.g., clindamycin), amphetamines), loop diuretics (e.g., furosemide), lysosomal enzymes (e.g., imiglucerase), macrolides (e.g., azithromycin), mast cell stabilizers (e.g., cromoglycin), meglitinides (e.g., repaglinide), melanocortin receptor antagonists (e.g., bumelantide), methylxanthines (e.g., theocorticoids), mineral corticosteroids (e.g., fludrocortisone), minerals and electrolytes (e.g., citric acid / potassium citrate), various antiviral agents (e.g., baloxavir mabaudiol), various anxiolytics, sedatives, and hypnotics (e.g., zolpidem), various bone resorption inhibitors (e.g., denosumab), various cardiovascular agents (e.g., midodrine), various central nervous system agents (e.g., dalfampridine), various coagulation agents regulators (e.g., tranexamic acid), various diuretics (e.g., pamabrom), various genitourinary agents (e.g., phenazopyridine), various gastrointestinal agents (e.g., misoprostol), various metabolic agents (e.g., brosuzumab), various respiratory agents (e.g., alpha-1-proteinase inhibitors), various topical agents (e.g., sodium hyaluronate), various vaginal agents (e.g., estradiol), mitotic inhibitors (e.g., vincristine), monoamine oxidase inhibitors (e.g., phenelzine), oral and throat products (fluoride), mTOR inhibitors (e.g., everolimus), expectorants (e.g., acetylcysteine), multichinase inhibitors (e.g., sorafenib), narcotic analgesic combinations (e.g., buprenorphine / naloxone), narcotic analgesics (e.g. fentanyl), natural penicillins (e.g. penicillin v potassium), neuraminidase inhibitors (e.g. oseltamivir), neuronal potassium channel openers (e.g. retigabine), new generation cephalosporins (e.g. ceftaroline), NHE3 inhibitors (e.g. ceftaroline), nicotinic acid derivatives (e.g. ethionamide), NK1 receptor antagonists (e.g. aprepitant), NNRTIs (e.g. efavirenz), non-cardioselective beta-blockers (e.g. carvedilol), non-sulfonylureas (e.g. metformin), nonsteroidal anti-inflammatory drugs (e.g. diclofenac), NS5A inhibitors (e.g. daclatasvir), nucleoside reverse transcriptase inhibitors (NRTIs) (e.g. tenofovir), nutritional preparations (e.g. omega-3 polyunsaturated fatty acids),Oral nutritional supplements (e.g., arginine), other immunostimulants (e.g., glatiramer), other immunosuppressants (e.g., omalizumab), anticonvulsant oxazolidinones (e.g., trimethoprim-sulfamethoxazole), antibiotic oxazolidinones (e.g., linezolid), parathyroid hormone and analogs (e.g., teriparatide), PARP inhibitors (e.g., niraparib), PCSK9 inhibitors (e.g., evolocumab), penicillinase-resistant penicillins (e.g., oxacillin), peripheral opioid receptor antagonists (e.g., naloxegol), mixed peripheral opioid receptor agonists (e.g., hegonist / antagonists), peripheral vasodilators (e.g., isoxsulin), peripherally acting weight loss agents (e.g., orlistat), phenothiazines Emetics (e.g., promethazine), phenothiazine antipsychotics (e.g., prochlorperazine), phenylpiperazine antidepressants (e.g., trazodone), potassium phosphate inhibitors (e.g., trazoderrone) (e.g., idelalisib), platelet aggregation inhibitors (e.g., aspirin), platelet stimulants (e.g., eltrombopag), polyenes (e.g., nystatin), potassium-sparing diuretics (e.g., spironolactone), probiotics (e.g., Lactobacillus acidophilus), progesterone receptor modulators (e.g., eplerenone), the progestin levonorgestrel), prolactin inhibitors (e.g., cabergoline), protease inhibitors (e.g., telaprevir), protease-activated receptor-1 antagonists (e.g., vorapaxar), proteasome inhibitors (e.g., bortezomib), proton pump inhibitors (e.g., omeprazole), psoralens (e.g., methoxsalen), purine nucleosides (e.g., valacyclovir), pyrrolidine anticonvulsants (e.g., levetiracetam), quinolones (e.g., ciprofloxacin), recombinant human erythropoietin (e.g., epoetin alfa), renin inhibitors (e.g., aliskiren), rifamycin derivatives (e.g., rifampicin), salicylates (e.g., aspirin), second-generation cephalosporins (e.g., selective cefuroxime receptor), modulators (e.g., ospemifene), selective immunosuppressants (e.g., natalizumab), selective phosphodiesterase 4 inhibitors (e.g., roflumilast), selective serotonin reuptake inhibitors (e.g., escitalopram), serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine), serotonin-derived neurotransmitters Enterogen modulators (e.g., tegaserod), SGLT-2 inhibitors (e.g., empagliflozin), skeletal muscle relaxants (e.g., botulinum toxin type A injections), smoking cessation agents (e.g., nicotine analogs, somatostatin) (e.g., octreotide), statins (e.g., lovastatin), streptogramins (e.g., dalfopristin / quinupristin), streptomyces derivatives (e.g., capreomycin), anticonvulsants succinimides (e.g., ethosuximide), sulfonamides (e.g., sulfamethoxazole), sulfonylurea stimulants (e.g., glimepistole), clomiphene), tetracyclic antidepressants (e.g., mirtazapine), tetracyclines (e.g., minocycline), thiazide diuretics (e.g., hydrochlorothiazide), thiazolidinediones (e.g., pioglitazone), thioxanthines (e.g., thiothixene),Third-generation cephalosporins (e.g., ceftriaxone), thrombin inhibitors (e.g., dabigatazone), strepolytic (e.g., levothyroxine), TNFα inhibitors (e.g., adalimumab), tocolytics (e.g., terbutaline), topical acne agents (e.g., tretinoin), local anesthetics (e.g., lidocaine), topical anti-infectives (e.g., marathon), topical anti-rosaceous agents topical antifungals (e.g., econazole), topical antihistamines (e.g., diphenhydramine), topical antineoplastic agents (e.g., imiquimod), topical antipsoriatics (e.g., tazarotene), topical antivirals (e.g., penciclovir), topical astringents (e.g., hazelnut), topical debridements (e.g., collagenase), topical depigmenting agents (e.g., hydroquinone), topical emollients (e.g., emollients), topical keratolytics (e.g., salicylic acid), topical nonsteroidal anti-inflammatory agents (e.g., diclofenac), topical photochemicals (e.g., aminolevulinic acid), topical rubefacients (e.g., menthol), topical steroids (e.g., betamethasone), topical steroids with anti-infectives (e.g., acyclovir / hydrocortisone), transthyretin stabilizers (e.g., clofazolin), triazine anticonvulsants (e.g., lamotrigine), tricyclic antidepressants (e.g., amitriptyline), urea cycle disruptors (e.g., sodium phenylbutyrate), urinary anti-infectives (e.g., nitrofurantoin), urinary antispasmodics (e.g., amitriptyline), modulators (e.g., potassium citrate), uterotonics (e.g., dinoprostone), vaginal anti-infectives (e.g., clindamycin), vasodilators (e.g., alprostadil), vasopressin antagonists (e.g., conivaptan), vasopressors (e.g., epinephrine), VEGF / VEGFR inhibitors (e.g., pazopanib), viral vaccines, vitamin / mineral combinations, vitamins (e.g., cyanocobalamin), VMAT2 inhibitors (e.g., valbenazine).
[0077] The active ingredients of the nutraceuticals can be vitamins (e.g., vitamins A, B, C, D, E, K, folic acid, biotin); minerals (e.g., potassium, chloride, sodium, calcium, phosphorus, magnesium, iron, zinc, manganese, copper, iodine, chromium, molybdenum, selenium, cobalt, fluorine); amino acids, peptides and proteins and their metabolites and derivatives (e.g., essential amino acids and branched-chain amino acids, carnosine, enzymes and enzyme complexes, lactoferrin, N-acetylcysteine, animal or plant food proteins); fatty acids (e.g., omega-3, omega-6, omega-9 fatty acids); natural products manufactured using whole sources or extracted or obtained from plants, animals, algae, fungi, lichens or bacteria (e.g., phytosterols, echinacea, green tea extract, garlic, aloe vera, fish oil, spiral algae, chlorella, digestive enzymes derived from fungi); sugars and polysaccharides (e.g., mannose, ribose, trehalose, glucose, glucuronolactone, dextrin); probiotics (e.g., live microorganisms such as Lactobacillus, Bifidobacterium, Saccharomyces boulardii); prebiotics (e.g., fructans such as oligofructose and inulin, galactans such as galacto-oligosaccharides and xylo-oligosaccharides); antioxidants (e.g., lipoic acid, coenzyme Q10, flavono, glutathione, resveratrol, catechins); other substances with nutritional or physiological effects, such as betaine, caffeine, theobromine, theophylline, CDP-choline, choline, creatine, phospholipids, GABA, glucosamine, inositol, melatonin, methylsulfonylmethane, nucleotides, squalene).
[0078] The inclusion of the active ingredient in the electrospun fiber can be achieved by co-electrospinning the active ingredient with the first compound. In this case, a mixture of the first compound to be electrospun, an electrospinning accelerator and the active ingredient can be prepared and the resulting mixture can be electrospun.
[0079] Alternatively, it is conceivable to electrospin the first compound alone and subsequently integrate the active ingredient into the resulting fibers. Depending on the application, it is contemplated that the active ingredient is absorbed in the electrospun fibers or is entrapped in the three-dimensional structure obtained with the electrospun fibers.
[0080] For example, the first compound to be electrospun may consist of a mixture of linear hyaluronic acid and cross-linked hyaluronic acid. The cross-linked hyaluronic acid has the effect of increasing the rigidity of the nanofibers obtained, but also increases the complexity of the three-dimensional structure of the film obtained by continuous deposition on several layers of the obtained fibers. Specifically, the presence of cross-linked hyaluronic acid leads to the formation of cavities in the film, which allow the molecules of the active ingredient to be accommodated.
[0081] According to another example, the active ingredient is a non-steroidal anti-inflammatory drug to be applied, for example, to skin burns. One or more analgesics may also be provided as additional active ingredients added to relieve the pain caused by burns. For this type of application, it is particularly advantageous that the first compound is a skin regeneration compound such as hyaluronic acid.
[0082] The use of the composition according to the invention in the treatment of skin burns is beneficial because it leads to a rapid absorption of the active ingredient as well as the first compound in the wound. In addition, the product obtainable by electrospinning the composition can be applied directly to the burn area. This improves the efficacy of the treatment.
[0083] Advantageously, the active ingredient is present in a concentration of 0.1% to 30% by weight, more preferably 0.2% to 20% by weight, even more preferably 0.5% to 10% by weight.
[0084] It should be noted that hyaluronic acid as the compound to be electrospun is a good candidate to be combined with different active ingredients of each of the three types as indicated above.
[0085] For example, among the cosmetic active ingredients, mention may be made of antiseborrheic agents (sebacic acid, azelaic acid), antioxidants (ascorbic acid, tocopherol, retinol, retinal), anti-plaque agents (glabridin, ammonium persulfate), emollients (witch hazel extract, bisabolol) and humectants (eg glycerol, propylene glycol).
[0086] Among the preferred nutraceutical active ingredients are natural products made using: whole sources or substances extracted or obtained from plants, animals, algae, fungi, lichens or bacteria (phytosterols, echinacea, green tea extract, garlic, aloe vera, fish oil, spirulina, chlorella, digestive enzymes derived from fungi), vitamins (e.g., vitamins A, B, C, D, E, K, folic acid, biotin) and antioxidants (e.g., lipoic acid, coenzyme Q10, flavonoids, glutathione, resveratrol, catechins).
[0087] The most favorable pharmaceutical active substances are androgens and anabolic steroids (e.g. testosterone), anti-CTLA-4 monoclonal antibodies (e.g. ipilimumab), anti-PD-1 monoclonal antibodies (e.g. nivolumab), antianginal agents (e.g. nitroglycerin), antiasthma drug combinations (e.g. diprophylline / guaifenesin), antibiotics (e.g. metronidazole), antibiotic / antineoplastic drugs (e.g. doxorubicin), antineoplastic drugs (e.g. isotretinoin), and antineoplastic drug combinations (e.g. letrozole / ribociclib).
[0088] It should be noted that such active ingredients may advantageously be combined with other compounds to be electrospun such as, for example, xanthan gum, guar gum, chondroitin sulfate, collagen or starch.
[0089] Another example of the composition comprises heparin as the compound to be electrospun and a pharmaceutically active ingredient, for example, an allergen extract or a platelet stimulator such as Eltrombopag.
[0090] According to an embodiment, the composition further comprises a stabilizer, which is preferably a cross-linkable polymer. An example of a stabilizer is sodium alginate, which should be added to the pullulan as a promoter. Preferably, the ratio of pullulan: alginate is 3:1.5 to 3:0.5, more preferably 3:1.
[0091] The present application also intends to protect a method for preparing the presently described composition, which method proposes mixing together the components of the composition in water or in an aqueous solution. It is proposed that all components can be mixed together at the same time or added sequentially. It is also proposed that each ingredient can be dissolved in a corresponding equal part of water and then the equal parts can be mixed together in order to obtain the composition, or that one or two components can be dissolved in one equal part.
[0092] It is preferred to add the surfactant some time before electrospinning as this makes the electrospinning more stable, resulting in more regular and defect-free electrospun fibers.
[0093] By the above method, electrospinning of the above composition results in the realization of one or more electrospun fibers, in particular nanofibers, forming a membrane substrate. Such a membrane substrate may be in the form of a nonwoven fabric.
[0094] The produced fiber consists essentially of the compounds of the above composition. Specifically, the fiber consists of the first compound to be electrospun, an electrospinning accelerator and a surfactant. If provided in the composition, the fiber also contains an active ingredient and / or a stabilizer.
[0095] With particular regard to active ingredients, it should be noted that the active ingredient can be integrated into the fibers by electrospinning the active ingredient with the rest of the composition, or the active ingredient can be separated from the fibers but inserted into the film substrate.
[0096] It has been observed that electrospun fibers can have a flat ribbon-like shape, ie, they have a flat or flattened cross-section.
[0097] Example
[0098] The following compositions were electrospun using industrial equipment:
[0099]
[0100] The composition was prepared by dissolving hyaluronic acid in 100 g of water, pullulan in 100 g of water, and surfactin and base in 36.5 g of water.
[0101] Three equal parts of water with the corresponding components are mixed together and the obtained solution is loaded into an industrial type equipment. It is possible to produce an A4 size fiber layer in 2 hours. It has been observed that the obtained fibers are regular and defect-free and have a substantially ribbon-like shape, i.e., they have a flat or flat cross section.
[0102] Obviously, modifications and / or additions of parts or steps may be made to the compositions and preparation methods described above without departing from the field and scope of the invention as defined by the claims.
[0103] It should also be clear that, although the present invention has been described with reference to some specific examples, those skilled in the art will of course be able to realize other equivalent forms of the composition to be electrospun, which have the characteristics set out in the claims and therefore all fall within the scope of protection defined by the claims.
Claims
1. A composition to be electrospun, the composition comprising: a first compound to be electrospun, the first compound to be electrospun being selected from xanthan gum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, cellulose derivatives, albumin, starch, gelatin, collagen, elastin, β-glucan, glycosaminoglycan, mucopolysaccharide, water-soluble polysaccharide and their derivatives; an electrospinning accelerator, the electrospinning accelerator being selected from alginate, pullulan and mixtures thereof; characterized in that, The composition also comprises a surfactant of biological and organic origin obtained by fermentation of Gram-positive microorganisms.
2. The composition according to claim 1, characterized in that The surfactant is a lipopeptide obtained from Bacillus sp.
3. The composition according to claim 2, characterized in that The surfactant is selected from the group consisting of surfactin, pyruvate and lichenin.
4. A composition according to any one of the preceding claims, characterized in that The concentration of the surfactant is 0.1-5% by weight of the total weight of the composition.
5. A composition according to any one of the preceding claims, characterized in that The composition has a pH of 6 to 7.
6. The composition according to claim 5, characterized in that The composition comprises a basic compound at a concentration of less than 2% by weight of the total weight of the composition.
7. A composition according to any one of the preceding claims, characterized in that The weight ratio between the first compound to be electrospun and the electrospinning accelerator is 2:1 to 1:
2.
8. A method for preparing a composition to be electrospun, the method comprising the steps of mixing a first compound to be electrospun with an electrospinning accelerator and a surfactant, wherein the first compound to be electrospun is selected from xanthan gum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, cellulose derivatives, albumin, starch, gelatin, collagen, elastin, β-glucan, glycosaminoglycan, mucopolysaccharide, water-soluble polysaccharides and their derivatives, the electrospinning accelerator is selected from alginate, pullulan and mixtures thereof, and the surfactant is of biological and organic origin obtained by fermentation of Gram-positive microorganisms.
9. The method according to claim 8, characterized in that The surfactant is a lipopeptide obtained from Bacillus sp.
10. The method according to claim 9, characterized in that The surfactant is selected from the group consisting of surfactin, pyruvate and lichenin.
11. The method according to any one of claims 8 to 10, characterized in that The method provides for mixing the first compound to be electrospun, the accelerator and the surfactant in respective separate aliquots of water and subsequently combining the aliquots of water.
12. The method according to any one of claims 8 to 11, characterized in that The method proposes mixing the first compound to be electrospun, the electrospinning accelerator and the surfactant together with an alkaline compound so as to maintain the pH of the mixture at 6 to 7.
13. A patch product comprising a film substrate capable of being absorbed by the skin, characterized in that: The membrane substrate is formed by at least one electrospun fiber based on a first compound to be electrospun, an electrospinning accelerator and a surfactant, wherein the first compound to be electrospun is selected from xanthan gum, pectin, chitin, chitosan, dextran, carrageenan, guar gum, agar, cellulose derivatives, albumin, starch, gelatin, collagen, elastin, β-glucan, glycosaminoglycan, mucopolysaccharide, water-soluble polysaccharide and their derivatives, the electrospinning accelerator is selected from alginate, pullulan and mixtures thereof, and the surfactant is of biological and organic origin obtained by fermentation of Gram-positive microorganisms.
14. The patch product according to claim 13, characterized in that: The at least one electrospun fiber has a flat ribbon shape.
15. The patch product according to claim 13 or 14, characterized in that: The surfactant is a lipopeptide obtained from Bacillus sp.
16. The patch product according to claim 15, characterized in that: The surfactant is selected from the group consisting of surfactin, pyruvate and lichenin.
Citation Information
Patent Citations
Dissolvable nano web porous film and method of preparing the same
CN102014962A
Preparation method of chitosan-pullulan electrostatic spinning composite nanofiber membrane
CN110129996A
Composition for electrostatic spinning
CN115038826A
Degradable and absorbable polymer nano fibrous membrane materials and preparation process and use thereof
CN1837274A
Hydrophilic synthetic fiber, fiber aggregate, product for skin contact and fiber treatment agent
JP2012057275A
